INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 31, 2014 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $52.03 | 35,711 |
| Dec 31, 2014 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | 37,079 |
| Nov 18, 2011 |
Director
Trans History: 111
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 25,000 |
| Sep 14, 2011 |
Director
Trans History: 547
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $20.97 | 35,000 |
| Sep 14, 2011 |
Director
Trans History: 547
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | -- |
| Jul 25, 2011 |
SVP Clinical Development
Trans History: 208
|
SVP Clinical Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $15.64 | 25,000 |
| Jul 25, 2011 |
SVP Clinical Development
Trans History: 208
|
SVP Clinical Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | 49,428 |
| Nov 12, 2010 |
Director
Trans History: 60
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 25,000 |
| Sep 29, 2008 |
SVP, Research & Devel Sciences
Trans History: 660
|
SVP, Research & Devel Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $8.77 | 25,350 |
| Sep 29, 2008 |
SVP, Research & Devel Sciences
Trans History: 660
|
SVP, Research & Devel Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.